ClinicalTrials.gg
CompletedNCT02509546Updated Nov 3, 2026Results posted

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of 8-Chloroadenosine and Laboratory Biomarker Analysis in Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by City of Hope Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by City of Hope Medical Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Posted results revisedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center — 15 open to participants now, 32 under way, none of them phase 3. Leukemia, Myeloid, Acute · City of Hope Medical Center.

Enrollment
34th of 57
20 · median 30
Started
2015
with 3 others
Phase 1/2
4 of 63
none open now
Registered
25th of 63
by date

Among the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 1/2, and was the 25th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as 8-chloroadenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (recommended phase II dose, RP2D) of 8-chloro-adenosine, when given as a single agent, in patients with relapsed or refractory acute myeloid leukemia. (Phase I) II. To assess tolerability and safety of 8-chloro-adenosine at each dose level by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase I) III. To estimate the response rate and to evaluate the antitumor activity of 8-chloro-adenosine, when given as a single agent, as assessed by complete remission rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]). (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate for disease response to 8-chloro-adenosine in refractory/relapsed acute myeloid leukemia (AML) on each dose level tested. (Phase I) II. To obtain estimates of remission duration and survival probabilities (overall and event-free). (Phase II) III. To obtain an estimate of the overall response rate (CR + CRi + partial response [PR]). (Phase II) IV. To summarize and evaluate toxicities by type, frequency, severity, attribution, time course and duration. (Phase II)

CLINICAL PHARMACOLOGY OBJECTIVES:

I. To describe the plasma, urinary and cellular pharmacokinetics of 8-chloro-adenosine and metabolites.

II. To determine the impact of 8-chloro-adenosine on cellular adenosine triphosphate (ATP) pool in AML blasts.

III. To assess the impact of 8-chloro-adenosine therapy on select short-lived messenger (m) ribonucleic acids (RNAs) and corresponding proteins in circulating AML blasts.

IV. To correlate clinical responses and toxicity with plasma/urine 8-chloro-adenosine level (pharmacokinetic [PK]), cellular 8-chloro-ATP (PK) and cellular ATP pool.

EXPLORATORY EX-VIVO MOLECULAR OBJECTIVES:

I. To determine the cytotoxicity of 8-chloro-adenosine toward leukemic progenitor cells in vitro.

II. To generate a preliminary pre-treatment RNA/micro RNA (miRNA) signature in leukemic progenitor cells, and explore its possible association with in vitro cytotoxicity to 8-chloro-adenosine.

III. To explore the possible association between the preliminary RNA/miRNA signature and clinical response to 8-chloro-adenosine.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive 8-chloro-adenosine intravenously (IV) over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 2 years.

03

Conditions studied

  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects must have the ability to understand and the willingness to sign a written
  • Patients must have a of > 3 months
  • Patients must exhibit an (ECOG) performance status of 0-2
  • Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
  • Patients must meet one of the three treatment history criteria:

    • AML who have failed at least 1 line of salvage therapy
    • De novo AML who have not achieved CR after 2
    • AML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder who have failed hypomethylating agent or induction chemotherapy
    • Patients who have relapsed after hematopoietic cell transplant (HCT) are eligible if they are at least 3 months after HCT, do not have active graft vs. host disease () and are off except for maintenance dose of (prednisone 10 mg/day or less)
  • At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 1
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 x (ULN)
  • Total =\< 1.5 X ULN
  • (QTc) =\< 480 ms
  • Calculated (CrCl) >= 50 mL/min per 24 hour urine collection or the Cockcroft-Gault formula
  • Negative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of only), to be performed locally within the screening period
  • Agreement by females of childbearing potential and sexually active males to use an effective method of (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation; the effects of study treatment on a developing fetus have the potential for teratogenic or abortifacient effects; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

Exclusion criteria

Exclusion Criteria:

  • Current or planned use of other agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period
  • Expected to undergo HCT within 120 days of enrollment
  • Current or planned use of agents that prolong or suspected to prolong
  • Diagnosis of acute promyelocytic leukemia
  • Active central nervous system leukemia
  • Active fungal infection or bacterial sepsis
  • Active peptic ulcer disease
  • History of heart failure or cardiac arrhythmia
  • Other active except for localized skin cancer, bladder, prostate, breast or cervical carcinoma in situ
  • Pregnant women and women who are lactating; 8-chloro-adenosine is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 8-chloro-adenosine, breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosine
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Phase I - 100mg/m^2 1-hour infusion

    100mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

  • Experimental
    Phase I - 200mg/m^2 1-hour infusion

    200mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

  • Experimental
    Phase I - 400mg/m^2 1-hour infusion

    400mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

  • Experimental
    Phase I - 800mg/m^2 1-hour infusion

    800mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

  • Experimental
    Phase I - 400mg/m^2 4-hour infusion

    400mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

  • Experimental
    Phase I - 600mg/m^2 4-hour infusion

    600mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.

    Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study

Interventions

  • Given IV

    Also known as: 8-Chloro-adenosine, 8-Cl-adenosine, 8-Cl-Ado

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherPharmacological Study

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)

    According to the standard 3+3 rules, where the highest DL that produced ≤ 1/6 DLTs in cycle 1 would be defined as the maximum tolerated dose (MTD). The RP2D of 8-Cl-Ado would generally be the MTD, but it could be less than the initially calculated MTD as determined from a review of the available data and cumulative toxicities from phase 1.

    Time frame: Up to 28 days following first study agent administration.

  2. Dose Limiting Toxicity (DLT)

    Toxicity was graded according to the NCI-Common Terminology Criteria for Adverse Events version 4.03. A DLT was defined as any of the following toxicities (please see the details in section of 13.2 of the protocol) that occur during cycle 1, per CTCAE version 4.03, and were considered related to the study drug.

    Time frame: Up to 28 days following first study agent administration.

Secondary outcomes

  1. Complete Remission Rate (CR + CRi)

    Complete remission rate (CR + CRi) based on the Döhner 2010 criteria and calculated as the percent of evaluable patients that have confirmed CR or CRi is to evaluate the antitumor activity of 8-chloro-adenosine.

    Time frame: Up to 2 years following first study agent administration.

07

Results

Posted Dec 5, 2023

Participant flow

Participant flow — Overall Study
MilestonePhase I - 100mg/m^2 1-hour InfusionPhase I - 200mg/m^2 1-hour InfusionPhase I - 400mg/m^2 1-hour InfusionPhase I - 800mg/m^2 1-hour InfusionPhase I - 400mg/m^2 4-hour InfusionPhase I - 600mg/m^2 4-hour Infusion
Started334226
Completed334226
Not completed000000

Outcome measures

PrimaryRecommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)

According to the standard 3+3 rules, where the highest DL that produced ≤ 1/6 DLTs in cycle 1 would be defined as the maximum tolerated dose (MTD). The RP2D of 8-Cl-Ado would generally be the MTD, but it could be less than the initially calculated MTD as determined from a review of the available data and cumulative toxicities from phase 1.

Time frame:
Up to 28 days following first study agent administration.
Reported as:
Number · mg/m^2
Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)
mg/m^2Phase I - Treatment (8-chloro-adenosine)
Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)400
PrimaryDose Limiting Toxicity (DLT)

Toxicity was graded according to the NCI-Common Terminology Criteria for Adverse Events version 4.03. A DLT was defined as any of the following toxicities (please see the details in section of 13.2 of the protocol) that occur during cycle 1, per CTCAE version 4.03, and were considered related to the study drug.

Time frame:
Up to 28 days following first study agent administration.
Reported as:
Count of participants · Participants
Dose Limiting Toxicity (DLT)
ParticipantsPhase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion
Dose Limiting Toxicity (DLT)001202
SecondaryComplete Remission Rate (CR + CRi)

Complete remission rate (CR + CRi) based on the Döhner 2010 criteria and calculated as the percent of evaluable patients that have confirmed CR or CRi is to evaluate the antitumor activity of 8-chloro-adenosine.

Time frame:
Up to 2 years following first study agent administration.
Reported as:
Number · Percent of evaluable patients
Complete Remission Rate (CR + CRi)
Percent of evaluable patientsPhase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion
Complete Remission Rate (CR + CRi)000000

Adverse events

Collected over Up to 2 years following first study agent administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion3/3 (100%)1/3 (33.3%)3/3 (100%)
Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion3/3 (100%)1/3 (33.3%)3/3 (100%)
Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion4/4 (100%)2/4 (50%)4/4 (100%)
Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion2/2 (100%)2/2 (100%)2/2 (100%)
Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion2/2 (100%)2/2 (100%)2/2 (100%)
Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion6/6 (100%)6/6 (100%)6/6 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPhase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion
CARDIAC ARRESTCardiac disorders0/30/31/41/20/20/6
MULTIORGAN FAILUREGeneral disorders and administration site conditions0/30/30/40/21/21/6
SEPSISInfections and infestations0/30/30/41/20/21/6
DISEASE PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/30/40/21/20/6
INVASIVE PULMONARY ASPERGILLOSISRespiratory, thoracic and mediastinal disorders0/30/30/41/20/20/6
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/30/30/40/20/22/6
PNEUMONIARespiratory, thoracic and mediastinal disorders1/30/30/40/20/20/6
LUNG INFECTIONInfections and infestations0/30/31/40/20/20/6
LEUKEMIANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/31/40/20/20/6
SUPRAVENTRICULAR TACHYCARDIACardiac disorders0/30/30/40/20/21/6
Most frequent other events
Showing 10 of 196
Most frequent other events
EventPhase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion
ANEMIABlood and lymphatic system disorders3/33/33/41/22/26/6
SINUS TACHYCARDIACardiac disorders1/33/33/41/20/26/6
VENTRICULAR TACHYCARDIACardiac disorders0/30/30/40/22/20/6
DIARRHEAGastrointestinal disorders2/33/32/40/20/23/6
NAUSEAGastrointestinal disorders1/32/33/42/21/24/6
FATIGUEGeneral disorders and administration site conditions1/31/32/41/22/24/6
FEVERGeneral disorders and administration site conditions0/31/34/42/20/23/6
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/31/30/42/20/23/6
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/30/30/42/20/24/6
BLOOD BILIRUBIN INCREASEDInvestigations3/33/32/42/22/26/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour InfusionTotal
Median75 (69 to 77)54 (28 to 66)59 (45 to 71)56 (50 to 63)68 (59 to 77)70 (61 to 75)66 (28 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Phase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour InfusionTotal
Female11321412
Male2210128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour InfusionTotal
Hispanic or Latino0211037
Not Hispanic or Latino31312313
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Phase I - 100mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 200mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 800mg/m^2 8-chloro-adenosine 1-hour InfusionPhase I - 400mg/m^2 8-chloro-adenosine 4-hour InfusionPhase I - 600mg/m^2 8-chloro-adenosine 4-hour InfusionTotal
United States33422620
08

Study locations

1 site
  • City of Hope Medical Center
    Duarte, California 91010, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Mar 2021, 65 months.

Results were first posted in Dec 2023, 2 years 8 months after primary completion.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's 65 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

Start moved once since we started tracking on Sep 25, 2026: Sep 2015 → Oct 2015, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2015
First posted
Jul 28, 2015
StartActual
Oct 5, 2015was Sep 2015
Primary completionActual
Mar 9, 2021
CompletionActual
Mar 16, 2021
Results first posted
Dec 5, 2023
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 3, 2026
Start date
Sep 2, 2015→Oct 5, 2015
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Posted results revised
    Start date Sep 2, 2015→Oct 5, 2015
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02509546
Responsible party
Sponsor
First posted
Jul 28, 2015
Start date
Oct 5, 2015
Primary completion
Mar 9, 2021
Completion
Mar 16, 2021
Results posted
Dec 5, 2023
Last update
Nov 3, 2026

Study contacts

Vinod Pullarkat
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 8-chloroadenosine

Start the discussion